154 related articles for article (PubMed ID: 28943968)
1. High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer.
Kim DH; Lee H; Kim DH; Chae SW; Sohn JH; Kim K; Do SI
Oncol Lett; 2017 Oct; 14(4):4995-5003. PubMed ID: 28943968
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of ERCC1 expression in breast cancer.
Gerhard R; Carvalho A; Carneiro V; Bento RS; Uemura G; Gomes M; Albergaria A; Schmitt F
Pathol Res Pract; 2013 Jun; 209(6):331-6. PubMed ID: 23702380
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.
Goyal S; Parikh RR; Green C; Schiff D; Moran MS; Yang Q; Haffty BG
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):679-84. PubMed ID: 19464815
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological correlation of the expression of excision repair cross complementation group 1 (ERCC1) in oral cavity squamous cell carcinomas: an immunohistochemical study.
Pankaj D; Guddattu V; Solomon MC
Exp Oncol; 2020 Jun; 42(2):135-139. PubMed ID: 32602295
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer.
Li Y; Liao X; Ma L
Front Oncol; 2022; 12():955719. PubMed ID: 36338712
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 expression in triple negative breast cancer.
Ozkan C; Gumuskaya B; Yaman S; Aksoy S; Guler G; Altundag K
J BUON; 2012; 17(2):271-6. PubMed ID: 22740205
[TBL] [Abstract][Full Text] [Related]
7. Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma.
Peng H; Yao S; Dong Q; Zhang Y; Gong W; Jia Z; Yan L
Medicine (Baltimore); 2018 Aug; 97(31):e11697. PubMed ID: 30075571
[TBL] [Abstract][Full Text] [Related]
8. Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract][Full Text] [Related]
9. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Italiano A; Laurand A; Laroche A; Casali P; Sanfilippo R; Le Cesne A; Judson I; Blay JY; Ray-Coquard I; Bui B; Coindre JM; Nieto A; Tercero JC; Jimeno J; Robert J; Pourquier P
Cancer; 2011 Aug; 117(15):3445-56. PubMed ID: 21287534
[TBL] [Abstract][Full Text] [Related]
10. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
Hasegawa K; Kato R; Torii Y; Ichikawa R; Oe S; Udagawa Y
Int J Gynecol Cancer; 2011 Nov; 21(8):1479-85. PubMed ID: 21720251
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
[TBL] [Abstract][Full Text] [Related]
12. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer.
He D; Ma X; Wu Z; Wang Y; Zhao S; Han F; Sun W
Oncol Lett; 2017 Sep; 14(3):3463-3472. PubMed ID: 28927101
[TBL] [Abstract][Full Text] [Related]
13. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?
Aksoy A; Elkiran ET; Harputluoglu H; Dagli AF; Isikdogan A; Urakci Z
J Cancer Res Ther; 2019; 15(3):550-555. PubMed ID: 31169219
[TBL] [Abstract][Full Text] [Related]
14. Role of ERCC1 expression in colorectal adenoma-carcinoma sequence and relation to other mismatch repair proteins expression, clinicopathological features and prognosis in mucinous and non-mucinous colorectal carcinoma.
Foda AA; Palicelli A; Shebl A; Boldorini R; Elnaghi K; ElHawary AK
Indian J Pathol Microbiol; 2019; 62(3):405-412. PubMed ID: 31361228
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy.
Zhou J; Wang D; Zheng JH; Wang Z; Xie B; Zhang WM
J Cancer Res Ther; 2018; 14(Supplement):S145-S151. PubMed ID: 29578165
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.
Song P; Yin Q; Lu M; Fu BO; Wang B; Zhao Q
Exp Ther Med; 2015 Apr; 9(4):1393-1400. PubMed ID: 25780441
[TBL] [Abstract][Full Text] [Related]
17. D2-40, Podoplanin, and CD31 as a Prognostic Predictor in Invasive Ductal Carcinomas of the Breast.
Lee JA; Bae JW; Woo SU; Kim H; Kim CH
J Breast Cancer; 2011 Jun; 14(2):104-11. PubMed ID: 21847404
[TBL] [Abstract][Full Text] [Related]
18. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics.
Li J; Sun P; Huang T; He S; Li L; Xue G
Medicine (Baltimore); 2021 Apr; 100(14):e25344. PubMed ID: 33832110
[TBL] [Abstract][Full Text] [Related]
19. [Importance of expression of DNA repair proteins in non-small-cell lung cancer].
Rybárová S; Muri J; Hodorová I; Vecanová J; Benický M; Piovarči D; Janík P; Mihalik J; Mirossay L
Klin Onkol; 2012; 25(5):370-4. PubMed ID: 23102199
[TBL] [Abstract][Full Text] [Related]
20. Elucidating the role of excision repair cross-complement group 1 in oral epithelial dysplasia and early invasive squamous cell carcinoma: An immunohistochemical study.
Kulkarni S; Solomon M; Pankaj D; Carnelio S; Chandrashekar C; Shetty N
J Oral Maxillofac Pathol; 2020; 24(1):20-25. PubMed ID: 32508443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
